Plain-English translation of NCT03571334 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether incobotulinumtoxinA (Xeomin®), a medication already used to treat other types of nerve pain, can help relieve the burning, tingling, and numbness that many breast cancer patients experience after chemotherapy. Half of the participants will receive injections of this medication into their hands or feet, while the other half will receive saline (salt water) injections as a comparison. The researchers want to see whether this treatment can reduce pain and improve quality of life.
Nerve pain after chemotherapy is very common and affects more than half of breast cancer patients who receive certain chemotherapy drugs. Current pain treatments don't work well enough for many people, so doctors are looking for better options. This medication has shown promise for treating other types of nerve pain, and researchers want to find out if it can help with chemotherapy-related nerve damage.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive a series of small injections either in your hands or feet (or both) — either the test medication or salt water as a comparison. The injections are placed in a grid pattern across 25 sites on each limb, using very small amounts at each spot. You'll be randomly assigned to receive either the medication or the comparison injection, and you won't know which one you're getting. The study team will follow up with you to measure how your nerve pain changes over time.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States